

# ANNUAL REPORT



#### Cover:

The Nixon Family takes on Relay For Life 2023 - cancer survivor Makayla Nixon (centre), her mother Claire, father Wayne, with siblings Caleb and Charlotte. Photo courtesy of Canberra Weekly.

#### **ACKNOWLEDGEMENT OF COUNTRY**

Cancer Council ACT acknowledges the Ngunnawal people as the traditional custodians of the ACT and surrounding areas. We pay our respects to Aboriginal and Torres Strait Islander cultures and to Elders past and present.

# **Contents**

**01** Organisation **02** Messages 03 Our Board Our Patron 04 Client Services **05** Research Funding **Fundraising Campaigns Financial Statements** 

# **Supporters**

#### **Transport Partner - Daffodil Car**

Subaru Canberra



#### **Client Services Partners**



**ACT Health** 



#### **Pro Bono Legal Partner**

#### MinterEllison.

#### **Community Fundraising Partners**









#### **Media Partners**





Canberra Weekly

#### Staff & Event Photography

Hilary Wardhaugh Photography

PAGE 1 ANNUAL REPORT 2022-23

# Strategic Plan 2022-25

**Our vision** A cancer free future

Our purpose To alleviate the impact of cancer in our community

Our values Accountability | Honesty | Empathy | Good Intent

**Our priorities** 



Our work will be underpinned by the voice of the ACT community, clients and carers, volunteers, health professionals, academics, and key policy and funding decision makers.

We will build strong relationships, leverage partnerships, and proactively engage with our stakeholders.



We will provide support for all those who are navigating the cancer system and will promote cancer awareness including prevention practices across the community.

We will ensure our services are effectively promoted so that we reach and support more people.



We will drive financial sustainability, revenue growth and diversification including using innovative approaches.

We will ensure a focus on efficiency, transparency, and return on investment to enable stronger service delivery.



We will ensure our support, prevention and information services meet the needs of the community.

We will continually revisit and test service delivery models to ensure they are maximising outcomes and will aspire to pursue development of new services to fill identified gaps.



We will proactively pursue opportunities to contribute to ACT-based cancer research.

We will look for ways to share our knowledge, experience, and promote the work of our research grant beneficiaries.



We will be a trusted voice for cancer patients and carers.

We will advocate to strengthen our impact in collaboration with the community, our beneficiaries and decision makers, giving a voice to the ACT.

# Reconciliation

Cancer Council ACT is proud to be joining the Reconciliation Action Plan program and, in doing so, making a formal commitment to advance reconciliation with Aboriginal and Torres Strait Islander communities.

As we take the first steps in our formal reconciliation journey, Cancer Council ACT has worked with renowned Ngunnawal artist Richard Allan to commission a custom artwork symbolising our values, which we are pleased to unveil as part of this report.



PAGE 3 ANNUAL REPORT 2022-23



#### About the artwork

The painting features a depiction of the native bluebell flower at its centre — a symbolic flower found on Ngunnawal land. The beauty of the flower symbolises the hope we bring, and the care that we give to each other in challenging times, and to people who are suffering due to cancer.

Surrounding the flower are seven circles representing the seven clans within Ngunnawal Country. The clans are joined as they connect with each other and with the beautiful land, creating a journey and forming the circle of life, which is vital in Ngunnawal culture.

The yellow and blue dots gathered around the circle of life signify people and families that always have been and always will be on Ngunnawal Country, the Ngunnawal people, and everyone from the Elders to those who live among the Ngunnawal people today, the Canberrans. The dots also represent the diverse and inclusive Cancer Council ACT community. All of us are going to be affected by cancer in our lifetime, as a supporter, a loved one, or going through our own cancer journey. Cancer is personal but it's all of us against cancer.

The patterns that lead into the flower represent the life of the Ngunnawal people and their livelihoods over the centuries. The wavy blue and yellow patterns symbolise the two important elements the Ngunnawal people needed to survive: the land and the water.

The white crossing patterns depict the fish nets that were woven by women using lomandra mat rushes to provide food, while the yellow lines and white dots illustrate the Ngunnawal tracking system, and the fish scales illustrate the fishing technique combined with the yellow wattle. These methods and practices allowed the traditional owners to take only what they need from the land and the water.

# **President's Foreword**

I am pleased to present the Annual Report for Cancer Council ACT for the 22-23 Financial Year. This year has been marked by both challenges and accomplishments, and I have enjoyed reflecting on our journey.

In the past fiscal year, we have faced economic uncertainties, but thanks to prudent financial management and the support of our donors, we have remained financially stable, allowing us to invest in critical programs and services. We have strived for transparency and accountability in managing the funds entrusted to us.

Throughout the year, we have focused on improving the accessibility and effectiveness of our programs and services, and have significantly increased our engagement with the ACT community. We are proud to have continued our efforts in cancer prevention, support, and advocacy for reducing the instance and impact of cancer.



Roger Buckley President

We have focused on expanding our reach into the community, providing educational resources, support groups, and assistance to those affected by cancer. The introduction of the Cancer Council ACT Hospital Liaison role in January 2023, delivered in partnership with the Canberra Region Cancer Centre (CRCC), was a highlight of the financial year, which I hope you will enjoy reading about in this report.

I am immensely grateful to our experienced Cancer Support Coordinators, who have provided the opportunity for those affected by cancer to talk about all aspects of the disease in a safe and supportive environment. Our ENHANCE Wellbeing and ENRICHing Survivorship programs have also continued to provide physical and emotional wellbeing support for those experiencing cancer, and those who have finished their treatment. I extend my gratitude to the volunteers and facilitators who have made all of these programs possible.

I would also like to recognise our Prevention Team this year who have made a significant positive impact in our community. Supporting the transition of the Alexander Maconochie Centre to a smoke-free environment was a major development of which we were very proud to be a part. The Prevention Team has limited resources, however through programs such as Tackling Tobacco they have extended their reach in the community, empowering both individuals and organisations.

The new financial year will bring its own set of challenges, but we are well-prepared to meet them headon. We will continue to advocate for improved cancer care, raise awareness, and invest in research that brings us closer to a cancer free future.

In closing, on behalf of the Board, I would like to thank Verity Hawkins, CEO, and all staff for their ongoing commitment and outstanding contributions.

Together, it really is all of us against cancer.

PAGE 5 ANNUAL REPORT 2022-23

# **CEO Report**

It is with great pleasure that I reflect on the last financial year, which has been a testament to our community's strength and resilience in the face of evolving challenges and uncertainties.

This year, Cancer Councils across Australia embraced a new message: it's all of us against cancer. The All of Us branding campaign promotes a holistic, unifying message, designed to underpin the entire organisation on a national level and expand across all of the work that we do. We know that cancer will affect all of us at some point – that is why Cancer Council exists: to unite all people, and all efforts, on all fronts towards a cancer free future.

Here in the ACT, we have truly seen the community embrace this message, with record-breaking fundraising efforts from inspiring individuals in the Canberra region. Our first 24-hour Relay For Life event since lockdowns was a huge success, raising over \$380,000, and I was especially honoured to welcome survivors, carers, and people experiencing cancer to this much-loved event. We also celebrated 30 years of Australia's Biggest Morning Tea, where nearly 400 people signed up to host morning teas around Canberra to support those in our community affected by cancer.

In addition to our important work in support and prevention, research remains at the forefront of our fight against cancer. This financial year, we have once again invested in groundbreaking research projects that hold promise for better treatments and, ultimately, a cancer free future. We awarded \$150,000 in research funding to Emeritus Professor Philip Board and Dr Olga Zaytseva via our annual Cancer Council ACT Research Grant program.

I sincerely thank our fundraisers, donors, and volunteers for making this financial year a success. I hope you enjoy reading about the progress we have made towards our mission to reduce the impact of cancer in the ACT.



Verity Hawkins Chief Executive Officer



Verity Hawkins with ACT Minister for Health, Rachel Stephen-Smith MLA at the launch of the ENRICHing Survivorship program.

# **Our Board**



Mr Roger Buckley
President and Cancer
Council Australia
Board Director



Mr Phil Greenwood OAM Board Vice-President, Finance Risk and Audit Committee Member



Mr Howard Pickrell Board Treasurer, Finance Risk and Audit Committee Chair



Professor Paul Craft AM
Board Honorary
Secretary, Research
Committee Chair



Ms Christine Brill Board Director, Finance Risk and Audit Committee Member



Ms Anne Kingdon Board Director, Governance Committe Chair



Mr Ardi Kachru Board Director, Governance Committee Member



Dr Denise Kraus Board Director, Research Committee Member

# **Our Patron**



#### Her Excellency Mrs Linda Hurley

We thank Mrs Hurley for her ongoing support as our Patron, and we are grateful for her shared commitment to a cancer free future. We extend our thanks to the Governor-General of the Commonwealth of Australia, His Excellency General the Honourable David Hurley AC DSC (Retd) for his support of our organisation.

PAGE 7 ANNUAL REPORT 2022-23

# Client Services













**SunSmart Education** 



Tobacco & e-cigarette Prevention Programs



Healthy Lifestyle

# Cancer Information & Support

Cancer Council ACT provides a range of cancer information and support services that includes a free and confidential call service on 13 11 20, a wide range of publications and resources, face to face support opportunities.

#### 13 11 20

13 11 20 is a free and confidential service staffed by healthcare professionals who can answer questions about all aspects of cancer, including prevention, early detection and treatment. They can also assist with practical and emotional support as well as referring you to appropriate services in the area.



#### **Publications and Resources**

All of our publications and information resources are evidence-based and clinically reviewed to meet the needs of those impacted by cancer. Our resources are available for anyone to download from our website and are available as printed booklets through our office. We also provide these resources to GP offices, clinics and Canberra Hospital.



#### **Community Events**

Cancer Council ACT healthcare professionals attend a range of community events where they have the opportunity to speak with members of the community impacted by cancer, supporting them with information and referrals to services.



PAGE 9 ANNUAL REPORT 2022-23

# Face-to-Face Support


Our healthcare professionals provide the same high-quality services as our 13 11 20 service with the added advantage of being in-person. Through our Hospital Liaison service and appointments at our Deakin offices, we help people navigate all aspects of cancer, providing information, support and referrals to services across the ACT.

#### **Hospital Liaison**

In January 2023, Cancer Council ACT, working in partnership with Canberra Health Services' Canberra Region Cancer Centre (CRCC), commenced the Cancer Council ACT Liaison role. The Liaison role enables our registered nurses to speak face-to-face with patients and their supporters providing information and support while they are waiting for their appointments or clinics.

The service provided by Cancer Council ACT has enhanced the services offered within the Canberra Region Cancer Centre. Patients, carers, family and friends are now able to have direct access to the information and support offered by Cancer Council ACT. This face-to-face, on-site contact is invaluable to patients undergoing treatment and we are very grateful to Cancer Council ACT for this service.





Liaison Officer off-site for people requiring further information or support. We will soon expand this service to the north side of Canberra.

Jan to June 2023





# Wellness Support Programs

Our professional healthcare staff coordinate the delivery of programs that provide information and support to those who have experienced cancer. This year, we have delivered four eight-week ENRICHing Survivorship programs.

#### **ENRICHing Survivorship**

ENRICHing Survivorship is a free exercise and nutrition program for cancer survivors funded by ACT Health through the Healthy Canberra Grants program. The program is facilitated by an exercise physiologist/physiotherapist, dietitian, yoga instructor and volunteers to improve participants' physical and emotional wellbeing after cancer treatment. The program runs one day per week for eight weeks, and each session is two hours long. ENRICHing Survivorship programs delivered in the last financial year received glowing feedback.

#### **Alan's Story**

Alan was diagnosed with Mantle cell lymphoma in October 2021. After going through chemotherapy and a stem cell transplant, Alan was told it would take about a year to get over it and to feel okay again. He started to go on walks after the stem cell transplant, but found it exhausting and had trouble getting his arms and legs to do what he wanted them to do. But mostly, Alan found it hard not being able to do the things he used to do before he was diagnosed with cancer.

Alan heard about the ENRICHing Survivorship Program and joined after six months of his stem cell transplant. Upon joining the program, Alan was looking to be inspired and to get back on track again. On day one, Alan was very excited to meet another person with his rare cancer, and learn about the shared experiences of other community members.



It was very good! The small group size made me feel comfortable and I got to know the other participants as well. It gave me the the ability to talk all things cancer and not see people cringe or want to hug me. Good to have others understand it, just like you do.

PAGE 11 ANNUAL REPORT 2022-23

# **Wig Service**

The Cancer Council ACT Wig Service provides a wide selection of wigs, turbans, hats, and beanies for people who have experienced hair loss due to cancer treatment. In a comfortable and confidential setting, our trained staff assist clients to find a piece of headwear that suits their needs.

During these wig service appointments, our registered nurses take the opportunity to talk with clients and provide support and information as needed. Support and information provided includes the provision of Cancer Council information booklets, to the clients, their families, carers, and friends. Cancer Council ACT considers these additional services to be fundamental to providing quality cancer care information and support.

We are very grateful for the support of The Snow Foundation and our donors who enable us to provide clients with one item of headwear at no cost.



Losing your hair due to cancer treatment can be a frightening and distressing experience. For information on hair loss and cancer, you can read our fact sheet or call our office for support.



Sharon Young, Wig Service client.

# SunSmart

The nationally accredited SunSmart program is an incredibly successful example of a long-running public health campaign that has shown significant benefits from a highly sustainable model. With a strong focus on system controls and policy support from the Cancer Council ACT Prevention Team, the SunSmart program reaches far beyond the five S's (slip, slop, slap, seek, slide) to protect Canberrans from the most commonly diagnosed, and most preventable cancer in Australia; skin cancer.

The Cancer Council ACT SunSmart Schools program achieved major milestones in the 2022-2023 financial year:









Alex Dreyer, Prevention Coordinator CCACT and Sid the Seagull present SunSmart School certification to Liz Bobos, Principal Majura Primary School and the Year 6 Leadership Team.

At Majura we take a lot of care to keep ourselves safe in the sun, so we are thrilled to be Cancer Council ACT's 100th school to register for the SunSmart program.

Liz Bobos, Majura Primary School Principal

PAGE 13 ANNUAL REPORT 2022-23

# Tobacco & e-cigarettes

The leading preventable cause of death and disease (including cancer) in Australia is tobacco. The Cancer Council ACT Prevention Team works to reduce the impact of tobacco and e-Cigarettes through initiatives such as workplace education workshops, community programs and online resources such as webinars. An example of one of our community programs is Tackling Tobacco.

#### **Tackling Tobacco**

The ACT Health-funded program has seen major developments in the area of tobacco cessation in this financial year. The program leverages the expertise and reach of ACT community service providers, and capacity-building training from Cancer Council ACT.


With five services registered, 48 staff trained, and hundreds of community clients reached, the program is one of a few examples of evidence-based and evaluated initiatives to provide judgement-free support to those in the ACT who are most likely to experience harm from smoking.

#### **Feedback**

We participate in the Tackling Tobacco program because we recognise that smoking rates within the LGBTIQA+ community are higher than the general population. Smoking rates are higher because research shows us that experiencing discrimination, trauma and social isolation are some of the most impactful reasons for taking up smoking.

Spokesperson, Meridian ACT





#### Support delivered to:

- People experiencing mental health issues
- Young people
- People who are LGBTIQA+
- People living with disability
- People experiencing homelessness
- Women and families experiencing domestic violence

#### AMC goes smoke free

The Cancer Council ACT Prevention team collaborated with ACT Corrective Services and the Smoke-Free AMC projects team between March and July 2023 to deliver brief intervention training to custodial officers, case management staff, and imprisoned people at the Alexander Maconochie Centre.

The Prevention Team undertook 17 education sessions that included harm minimisation programs and the support available through Quitline counselling. Additionally, the team also setup an online information portal for participants to access updated information and support.







L-R: Alex Dryer, CCACT Prevention Coordinator; Verity Hawkins, CCACT CEO; Michael Steen, Project Director ACT Corrective Services; Bruno Aloisi, Acting Commissioner ACT Corrective Services.

#### **Feedback**

Staff conveyed that said the sessions helped them feel more confident in helping imprisoned people overcome the physical and emotional challenges of quitting. After the ban, they are handling it well and are already noticing that they didn't feel the urge to smoke as much now as they weren't seeing or smelling it. Many were already seeing the benefits to their sleep and physical fitness, and the health of those around them.

Spokesperson, AMC



PAGE 15 ANNUAL REPORT 2022-23

# Research

We are committed to funding research into all aspects of cancer, including cancer prevention, detection and treatment, as well as understanding the psychological and social impact of the disease. We congratulate the 2023 Cancer Council ACT Research Grant Program recipients, who both work in the John Curtin School of Medical Research at ANU.

#### **Emeritus Professor Philip Board**

Australian National University

Testing GSTO1 inhibitors as anti-cancer therapeutics.

Professor Board's project will determine whether the GSTO1 inhibitors his team has developed can slow or block the growth of different cancers, which may provide a new approach to the treatment of drugresistant cancers. His team will test the capacity of the inhibitors to prevent the survival of breast cancer stem cells, which are often the cause of a relapse after chemotherapy.



Emeritus Professor Philip Board. Photo courtesy of ANU.



Dr Olga Zayetseva.

#### Dr Olga Zaytseva

Australian National University

Understanding how FUBP1 drives primary brain cancer towards rational drug discovery.

New research strategies are urgently needed if we are to improve brain cancer patient outcomes, as there have been genetic mutations identified in brain cancer that we don't yet fully understand. Dr Zayetseva is using her research grant to mimic the same mutations in fly cells, in order to learn about how they cause the cells to go awry and initiate cancer.

#### The Australian National University **Cancer Council ACT Pathology Prize**

We were pleased to once again partner with the ANU Medical School in presenting the Year Four Pathology Prize, to inspire the next generation of cancer researchers. Congratulations to 2022 recipient, Kate Phillips.



"I have loved pathology since my first class in medical school, and being awarded this prize is a moving recognition of my hard work, as well as a testament to the exceptional quality of the academic staff at ANU and Canberra Hospital. Thank you again to Cancer Council ACT for their support and inspiration of young doctors like myself."



Kate receiving the award at the 2022 ANU MChD Graduation Ball. Photo courtesy of ANU.

# Fundraising Campaigns

EVERY DOLLAR RAISED
IN THE ACT, STAYS IN THE ACT





**Biggest Morning** 

Tea





Daffodil Day



The Longest Day



Dry July





**Appeals** 

#### **Relay For Life 2023**

Relay For Life is a fun and moving experience that raises vital funds for our research, prevention and support services. Relay For Life is a chance for the community to recognise and celebrate local cancer survivors, those going through a cancer experience and their carers, to honour and remember loved ones lost and to raise money to help save more lives.





# THIS YEAR RELAY FOR LIFE ACT SUCCESSFULLY RAISED OVER \$390,000 WITH THE HELP OF 1,217 RELAYERS.

#### Return of the traditional 24-hour relay

Fully supported by Relay For Life's official committee of volunteers, this year saw the return of the 24-hour relay with a festival-like concept bringing together local communities, celebrating cancer fighters, survivors, and their carers. Relaying for 24 hours serves as an important reminder that cancer does not stop, whilst raising much-needed funds for cancer research, prevention, and support programs.



The Bold Bandannas are the longest running Relay For Life team in the ACT, and will celebrate their 25th year in 2024

The average amount raised per team this year was \$3,683.00 with our highest fundraising team, the Bold Bandannas raising

\$77,297



#### **Australia's Biggest Morning Tea**

Each year across May and June, the community comes together to raise a cup for Australia's Biggest Morning Tea.

We were honoured to once again be hosted at Government House by His Excellency, General the Honourable David Hurley AC DSC (Retd) and Her Excellency Mrs Linda Hurley, Cancer Council ACT Patron for a Biggest Morning Tea celebration to thank our volunteers and formally award the 2023 Cancer Council ACT Research Grant recipients.

The campaign celebrated its 30th birthday this year and thanks to the enormous support from our fundraisers, we surpassed our fundraising goal for the campaign. Every dollar raised has made an incredible difference to those impacted by cancer.



# THIS YEAR THE CAMPAIGN RAISED OVER \$194,000 THANKS TO THE 382 MORNING TEA HOSTS



Clockwise from top: Fundraisers from Capital Chemist (x 2), Her Excellency Mrs Linda Hurley and Board Director Christine Brill at Government House, Verity Hawkins and Senator David Pocock at the Legislative Assembly.

PAGE 19 ANNUAL REPORT 2022-23

#### **Do It For Cancer**

Do It For Cancer is a unique fundraising platform, enabling the community to host their own event or activity at any time of the year to raise funds for cancer. Fundraisers can do something active, host an event, give wedding favours and more - the sky is the limit. Our goal is to give hosts the support they need to execute a successful event without interfering with their creativity.



# THIS FINANCIAL YEAR, THE COMMUNITY RAISED OVER \$67,000 WITH THE SUPPORT OF 30 FUNDRAISERS

#### **Emily's Story**

Motivated by her school friend's cancer diagnosis, Emily embarked on a mission to raise funds for cancer. She made a heartfelt commitment to let her hair grow for an entire year, with the ultimate goal of having it cut on her 10th birthday. Through her dedication and efforts, Emily successfully raised more than \$1,100 for the cause.



I have been growing my hair to donate to help people suffering with cancer as they can lose their hair during treatment.

I'm challenging myself to cut my hair to support the Cancer Council in their mission for a cancer free future.

Because 1 in 2 Australians will be diagnosed with cancer in their lifetime, I'm losing my locks to raise funds and show my support.

#### **Daffodil Day**

Daffodil Day is one of Cancer Council ACT's most iconic and much-loved fundraising campaigns. This was our first in-person Daffodil Day since 2019, with 10 stalls across Canberra.

The campaign raised almost \$80,000 for life-saving cancer research in the ACT. Daffodil Day also symbolises hope, resilience, and unity in the fight against cancer.



L-R: Kara Tedman, Cancer Council ACT Volunteer and Roger Buckley, Cancer Council ACT President at Southpoint Tuggeranong Daffodil Day 2022 booth.

#### **The Longest Day**

The Longest Day is a fundraising golf marathon where each participant tests their golfing skills, strength, and stamina.

The ultimate challenge is to play from dusk to dawn and complete 72 holes to raise funds for Cancer Council ACT's research, prevention, and support services.

In 2022, we raised almost \$50,000 surpassing our target of \$30,000 supported by 77 participants.



The Big Sticks team at the Murrumbidgee Country Club fundraising for Cancer Council ACT on The Longest Day 2022.

PAGE 21 ANNUAL REPORT 2022-23



#### **Dry July**

Dry July is a fundraiser led by the Dry July Foundation that encourages participants to go alcohol-free in July to raise funds for people affected by cancer.

This year the ACT raised over \$31,000.



#### **The March Charge**

The March Charge is a fun fitness challenge that anyone can join as an individual or a team to walk or run in the month of March and raise funds for cancer.

This year the campaign raised over \$38,000.



#### **Appeals**

Cancer Council ACT conducted two major appeals this financial year: our annual Christmas Appeal and Tax Appeal.

Thanks to the generosity of the community this financial year, we raised nearly \$100,000.

Cancer Council ACT would like to thank all fundraisers and donors for their generosity. We are grateful for your help in raising vital funds for local research and support to people affected by cancer in the ACT.

# **Thank You**

Cancer Council ACT gratefully acknowledges all those who have donated to our organisation in the 2022-2023 financial year, including those who have given anonymously.

#### **Major Donors**

We especially thank those who have made significant contributions to our work through substantial fundraising efforts and major gifts:

The Lidia Perin Foundation Edwin Gibbons Margaret & Douglas Prescott

Michael Adler Ross Gough Deb Purdon
Erik Beens Peter & Karen Hitchcock Wendy Rainbird

Warwick Beutler Yen Huynh Michael & Margaret Roach

Warwick Bray Toni Irvine Stephen Rothwell
Maureen Chan Ielena Kovac Les Swain

Gayathri Chandula

Belinda Lewis

Susan Dejager

Neil Mackenzie

Ruth & Neale Wootton

John Fitzgerald

Robert McDonald

Dudley & Eva Yager

Colin French Stephen & Emma McFarlane

Avis Gesling Stephen Peilschmidt

#### **Top fundraisers**

The Bold Bandanas | Relay For Life
Allianz ACT | Australia's Biggest Morning Tea
Murrumbidgee Members | The Longest Day
Melissa Wallwork | Daffodil Day

Belconnen Golf Club Magpies | Do It For Cancer

#### **Bequests**

We acknowledge and thank those and their families who have chosen to honour us with a gift in their will or through a memorial fund.

Colin Telfer Memorial Fund

The estates of: GJ Jackson, John William

Anna Oszlanszki Memorial Fund

Wallis, Norma Olwyn Gray, Danila Emelia

Johanna Wyld Memorial Fund Marinolli, Colin Robert Messer, and Valerie

Benny Therp-Olesen Memorial Fund Clements.

With thanks to The Capital Region Community Foundation (GreaterGood) for connecting the community with our cause.

PAGE 23 ANNUAL REPORT 2022-23

#### **SUBARU CANBERRA: DRIVING HOPE**

Cancer Council ACT sincerely thanks Jon Dudok and Subaru Canberra for the ongoing contribution of the Subaru Daffodil Car to our organisation, which has been essential to our operations. This financial year, the Daffodil Car once again made a significant contribution to our ability to serve the community and support those affected by cancer.

In the last financial year, the Subaru Daffodil Car has taken us all over Canberra, educating the community and helping those affected by cancer. Just some of the places the Daffodil Car has been are shown below:





ANNUAL REPORT 2022-23 PAGE 24

Council

# **Financial Statements**

#### For the year ended 30 June 2023

| Directors' Report  | 1  |
|--|----|
| Auditor's Independence Declaration                         | 6  |
| Statement of Profit or Loss and Other Comprehensive Income | 7  |
| Statement of Financial Position                            | 8  |
| Statement of Changes in Equity                             | 9  |
| Statement of Cash Flows                                    | 10 |
| Notes to the Financial Statements                          | 11 |
| Directors' Declaration                                     | 23 |
| Independent Auditor's Report                               | 24 |
|  |    |

ABN: 33 113 296 601

#### **Directors' Report**

#### For the Year Ended 30 June 2023

The Directors present their report on The Cancer Council ACT (the Company) for the financial year ended 30 June 2023.

#### **Information on Directors**

The names of each person who has been a director during the year and to the date of this report are:

| Director   | Date of Appointment, Occupation, and Other Directorships  | Responsibility                      |
|--|---|-------------------------------------|
| Mr Roger Buckley JP<br>BBA, MC   | Appointed: 9 May 2016 Sole Trader – Registered Marriage Celebrant Director – Cancer Council Australia Member – Australian Federation of Civil Celebrants Member – Cancer Council Chairs Forum                   | President<br>Board Nominee          |
| Mr Phil Greenwood OAM JP   | Appointed: 20 March 2018<br>Occupation: Retired CEO<br>Other Directorship: Rotary Club Tuggeranong<br>Member – Probus<br>Police Volunteer   | Vice President<br>Board Nominee     |
| Dr Paul Craft AM<br>MBBS, MPH, FRACP   | Appointed: 3 July 2013 Occupation: Medical Oncologist, The Canberra Hospital; Associate Professor Medical Oncology, ANU Medical School; Clinical Director, Cancer and Ambulatory Support, The Canberra Hospital | Board Nominee                       |
| Mr Howard Pickrell<br>B Sci Agriculture;<br>Chartered Accountant (CA)                              | Appointed: 21 February 2017<br>Occupation: Chief Operating Officer, Australian Christian<br>Lobby Ltd<br>Other Directorships: Nil   | Treasurer<br>Board Nominee          |
| Ms Christine Brill JP<br>Grad Cert Mgt, Grad Dip Empl Rel<br>M.HRM, FSAE, FAHRI,<br>AFACHSM, MAICD | Appointed: 20 September 2001 Occupation: Retired NFP CEO & Company Secretary Other Directorships: Nil   | Honorary Secretary<br>Board Nominee |
| Mr Ardi Kachru   | Appointed: 21 November 2019 Occupation: Assistant Director of Marketing, Department of Veterans' Affairs Other Directorships: Nil   | Board Nominee                       |
| Dr Denise Kraus  | Appointed: 21 November 2019 Occupation: General Practitioner Member: Australian College of General Practitioners Member: Australia Medical Association Member: Medical Women's Society (ACT)                    | Board Nominee                       |
| Ms Anne Kingdon  | Appointed: 21 November 2019<br>Occupation: Retired Lawyer<br>Secretary - Tuross Heads Rural Fire Service  | Board Nominee                       |

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated above.

ABN: 33 113 296 601

#### **Directors' Report**

#### For the Year Ended 30 June 2023

#### **Meetings of Directors**

During the financial year, seven meetings of directors were held. Attendances by each director during the year were as follows:

|                    | Directors' Meetings       |                 |  |  |
|--------------------|---------------------------|-----------------|--|--|
|                    | Number eligible to attend | Number attended |  |  |
| Mr Roger Buckley   | 7                         | 7               |  |  |
| Mr Phil Greenwood  | 7                         | 6               |  |  |
| Dr Paul Craft      | 7                         | 4               |  |  |
| Ms Howard Pickrell | 7                         | 7               |  |  |
| Ms Christine Brill | 7                         | 7               |  |  |
| Mr Ardi Kachru     | 7                         | 6               |  |  |
| Dr Denise Kraus    | 7                         | 6               |  |  |
| Ms Anne Kingdon    | 7                         | 6               |  |  |
|                    |                           |                 |  |  |

#### **Company Secretary**

Verity Hawkins remains in the position of Company Secretary to which she was appointed on 23 November 2021.

#### **Principal Activities**

The principal activities of the Company during the financial year were to provide cancer information, support and prevention services.

#### **Operating Results**

The net operating result for the Company was a surplus of \$32,685 (2022: deficit of \$281,805).

#### Significant Changes in State of Affairs

There were no significant changes in the state of affairs of the Company that occurred during the financial year.

#### **Objectives and Strategies**

#### Long and short term objectives of the entity

The long-term objective of the Company is to decrease the incidence and impact of cancer in the ACT.

The short-term objectives are directed towards funding and delivering programs and support that have a tangible impact on people affected by cancer, including cancer education and prevention, support programs, advocacy and provision of local cancer research grants.

ABN: 33 113 296 601

### **Directors' Report**For the Year Ended 30 June 2023

#### **Objectives and Strategies (continued)**

#### Our strategies for achieving those objectives

Strategies to achieve both short and long-term objectives include using the most appropriate evidence-based activities and tools to ensure the Company realises its vision of a Cancer Free Future. This includes maintaining a portfolio of fundraising activities which engages those who share our vision, by matching their capacity and motivation to donate revenue. Building and maintaining a diverse range of skills within the Company's workforce will enable the organisation to continue to deliver high quality services to its clients and customers.

#### Principle activities during the year and how those activities assisted in achieving objectives

Cancer Information, Support Services and Supportive Care for cancer patients and those affected by a diagnosis of cancer.

- Telephone information and support (13 11 20) as well as referrals to relevant Cancer Council and external service providers (eg: legal and financial planning referral service). Provision of cancer-related publications, interactive and supportive online services and access to information regarding all cancers via the Cancer Council ACT website.
- Supply of discounted wigs to people losing their hair as a result of their cancer treatment.
- Support groups for people affected by cancer.
- Free education programs including Living With Cancer and the Legal and Financial Matters seminars.

#### Cancer Prevention and Early Detection Program

- Smoking cessation, education and cancer prevention courses and workshops as well as one-on-one interventions to help people quit or not begin smoking at all.
- SunSmart education and skin cancer prevention information provided to early childhood centres, schools (especially primary) and organisations and businesses that have an outdoor workforce.

#### Research Program

 Provision of funds for cancer research and related projects in the ACT, reviewed (and Board approved), annual cancer research grants.

#### Fundraising and Business Development Program

The planning, coordination and successful execution of major fundraising campaigns, including Relay For Life, Australia's Biggest Morning Tea, Daffodil Day and other Cancer Council ACT and community-initiated events and activities to support the provision of services to the greater ACT region.

Direct Marketing - donations to support the services provided by Cancer Council ACT.

The regular giving program encourages individuals to support Cancer Council ACT by making regular donations throughout the year. Direct Marketing appeals also promote consideration of bequests in Wills, to assist in the ongoing provision of Cancer Council ACT community support and education.

ABN: 33 113 296 601

#### **Directors' Report**

#### For the Year Ended 30 June 2023

#### **Measurement and Performance**

#### How the Company measures its performance, including any key performance indicators used by the entity

The Company currently receives one continuing service funding arrangement from ACT Health to assist the provision of cancer information, prevention and support services. The services to the community are also partly funded by the Company's fundraising initiatives.

For the 12 months ended 30 June 2023, Cancer Council ACT used the Outputs and Performance Indicators required by ACT Health (ACT Government) as minimum performance indicators for the provision of these services. The aim is to exceed any quantitative and qualitative Performance Indicators set, including, for example, the number of hours of support provided, and the number of courses and workshops held. A report is provided to ACT Health every six months.

The Company was also the successful recipient of the following three-year grants through The ACT Government's Health Promotion Grants program:

- Tackling Tobacco Program.
- ENRICHing Survivorship Program.

The Company assesses its overall effectiveness in a number of ways and includes both qualitative and quantitative measures. These include monitoring the number of calls to the 13 11 20 number, wig service referrals and by email and drop-in enquiries. The number of requests for hard copy information and the number of website page hits for specific topics is another measure. General community awareness about Cancer Council ACT is important to ensure those with a diagnosis of cancer and their families know what services are available. Regular engagement with local media, as well as with our following on social media, is helping to boost this awareness and ensuring the organisation remains connected to the broader community.

#### **Dividends**

The Company is limited by guarantee and is prohibited by its objects from distributing any surplus to the members. Accordingly no dividend has been paid or declared by the Company since the end of the previous financial year and up to the date of this report.

#### **Company Limited by Guarantee**

The Company is limited by guarantee. If the entity is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the Company. At 30 June 2023 the number of members was 15 (2022: 17).

#### **Events after the Reporting Date**

There has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature likely, in the opinion of the directors, to affect substantially the operations of the Company, the results of those operations or the state of affairs of the Company in subsequent financial years.

#### **Directors' Benefit**

Since the end of the previous financial year, no director has received or become entitled to receive a benefit by reason of a contract made by the Company or a related corporation with the director or with a firm of which he/she is a member, or with a company in which he/she has a substantial financial interest, except any benefit that may be deemed to accrue by reason of professional costs paid in the ordinary course of business.

ABN: 33 113 296 601

#### **Directors' Report**

#### For the Year Ended 30 June 2023

#### **Indemnification of Officers or Auditors**

Every member of the Board, Auditor, Secretary and other officer for the time being of the Company shall be indemnified out of the assets of the Company against any liability arising out of the execution of the duties of their office which is incurred by them in defending any proceedings, whether civil or criminal, in which judgement is given in their favor or in which they are acquitted or in connection with any application under the Law in which relief is granted to them by the Court in respect of any negligence default, breach of duty or breach of trust.

The Company has paid a premium during the financial year in respect of an insurance contract insuring the directors and officers against a liability incurred as an officer for the costs of rexpenses to defend legal proceedings.

#### Auditor's independence declaration

The auditor's independence declaration for the year ended 30 June 2023 has been received and can be found on page 6 of the financial report.

Signed in accordance with a resolution of the Board of Directors:

| Director: . | J. Julles | Director: Hadel CA |  |
|-------------|-----------|--------------------|--|
| Dated this  | 25th      | day ofOctober 2023 |  |



Nexia Canberra

Level 5, 17 Moore Street Canberra ACT 2601 GPO Box 500 Canberra ACT 2601 P: +61 2 6279 5400 nexia.com.au

# Auditor's Independence Declaration Under Subdivision 60-40 of the Australian Charities and Not-for-profits Commission Act 2012 to the Directors of The Cancer Council ACT

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2023 there have been no contraventions of the auditor independence requirements as set out in any applicable code of professional conduct in relation to the audit.

Nexia Duesburys (Audit) Canberra, 25 October 2023

min Muller

G J Murphy Partner

Journ Musly

ABN: 33 113 296 601

# Statement of Profit or Loss and Other Comprehensive Income For the Year Ended 30 June 2023

| No   | ote  | 2023<br>\$  | 2022<br>\$  |
|--|------|-------------|-------------|
|  |      | •           | •           |
| Revenue Revenue from contracts with customers    | 2    | 580,516     | 403,030     |
|  | 2    | 1,908,683   | 1,496,495   |
|  | _    | _           | _           |
|  | _    | 2,489,199   | 1,899,525   |
| Expenses   |      |             |             |
| Board expenses                                   |      | 16,300      | 13,485      |
| Client resources                                 |      | 38,033      | 68,177      |
| Consultancies                                    |      | 33,340      | 49,700      |
| Depreciation and amortisation expenses           |      | 114,599     | 97,124      |
| Employee benefits expense                        |      | 1,329,253   | 1,221,587   |
| Fundraising expenses                             |      | 164,592     | 110,991     |
| Insurance  |      | 12,702      | 16,044      |
| Interest on lease liabilities                    |      | 32,155      | 34,401      |
| Loss on disposal of assets                       |      | -           | 2,168       |
| Membership                                       |      | 129,794     | 109,371     |
| Occupancy expenses                               |      | 27,176      | 19,005      |
| Other expenses                                   |      | 237,178     | 205,017     |
| Research grants                                  |      | 173,636     | 130,250     |
| Superannuation                                   |      | 123,578     | 100,341     |
| Wig merchandise                                  | _    | 24,178      | 3,669       |
|  | _    | (2,456,514) | (2,181,330) |
| Surplus/(deficit) for the year before income tax |      | 32,685      | (281,805)   |
| Income tax expense 1(                            | a) _ | -           | -           |
| Surplus/(deficit) for the year                   |      | 32,685      | (281,805)   |
| Other comprehensive income                       | _    | -           |             |
| Total comprehensive income for the year          | _    | 32,685      | (281,805)   |

ABN: 33 113 296 601

#### **Statement of Financial Position**

#### As At 30 June 2023

|   | Note     | 2023<br>\$       | 2022<br>\$       |
|---|----------|------------------|------------------|
| ASSETS  |          |                  |                  |
| CURRENT ASSETS                                  |          |                  |                  |
| Cash and cash equivalents                       | 3        | 3,384,137        | 3,440,417        |
| Trade and other receivables                     | 4        | 307,425          | 231,086          |
| Inventories Other assets                        | 5        | 13,127<br>25,729 | 15,063<br>38,817 |
| TOTAL CURRENT ASSETS                            | · -      | •                |                  |
|   | _        | 3,730,418        | 3,725,383        |
| NON-CURRENT ASSETS                              | 2        | 44.000           | 45.705           |
| Property, plant and equipment Intangible assets | 6<br>7   | 11,829<br>64,053 | 45,735<br>56,330 |
| Right-of-use assets                             | 9        | 684,039          | 747,752          |
| TOTAL NON-CURRENT ASSETS                        | <b>–</b> |                  |                  |
|   | _        | 759,921          | 849,817          |
| TOTAL ASSETS                                    | =        | 4,490,339        | 4,575,200        |
| LIABILITIES CURRENT LIABILITIES                 |          |                  |                  |
| Trade and other payables                        | 8        | 224,945          | 243,670          |
| Lease liabilities                               | 9        | 55,766           | 52,125           |
| Contract liabilities                            | 10       | 96,725           | 136,341          |
| Employee benefits                               | 11 _     | 41,658           | 48,739           |
| TOTAL CURRENT LIABILITIES                       |          | 419,094          | 480,875          |
| NON-CURRENT LIABILITIES                         | _        |                  |                  |
| Lease liabilities                               | 9 _      | 687,592          | 743,357          |
| TOTAL NON-CURRENT LIABILITIES                   |          | 687,592          | 743,357          |
| TOTAL LIABILITIES                               |          | 1,106,686        | 1,224,232        |
| NET ASSETS                                      | _        | 3,383,653        | 3,350,968        |
| FOULTY  |          |                  |                  |
| EQUITY Retained earnings                        |          | 3,383,653        | 3,350,968        |
| TOTAL EQUITY                                    | _        | 3,383,653        | 3,350,968        |
|   | =        | -,,              | -,0,000          |

ABN: 33 113 296 601

# **Statement of Changes in Equity**

For the Year Ended 30 June 2023

2023

|                         | Retained<br>Earnings<br>\$ | Total<br>\$ |
|-------------------------|----------------------------|-------------|
| Balance at 1 July 2022  | 3,350,968                  | 3,350,968   |
| Surplus for the year    | 32,685                     | 32,685      |
| Balance at 30 June 2023 | 3,383,653                  | 3,383,653   |
| 2022                    | Retained<br>Earnings       | Total       |
|                         | \$                         | \$          |
| Balance at 1 July 2021  | 3,632,773                  | 3,632,773   |
| Deficit for the year    | (281,805)                  | (281,805)   |
| Balance at 30 June 2022 | 3,350,968                  | 3,350,968   |

ABN: 33 113 296 601

## **Statement of Cash Flows**

# For the Year Ended 30 June 2023

|   | Note | 2023<br>\$  | 2022<br>\$  |
|---|------|-------------|-------------|
| CASH FLOWS FROM OPERATING ACTIVITIES:                     |      |             |             |
| Receipts from donations, special events and others        |      | 1,889,912   | 1,573,520   |
| Grants receipts   |      | 559,051     | 423,427     |
| Interest received   |      | 15,331      | 6,627       |
| Interest on lease liabilities                             |      | (32,155)    | (34,401)    |
| Payments to suppliers and employees                       | _    | (2,411,619) | (2,100,104) |
| Net cash provided by/(used in) operating activities       | _    | 20,520      | (130,931)   |
| CASH FLOWS FROM INVESTING ACTIVITIES:                     |      |             |             |
| Payments for property, plant and equipment                |      | (6,514)     | (23,577)    |
| Cost of development of intangible asset                   |      | (18,189)    | (56,330)    |
| Proceeds from sale of property, plant and equipment       | _    | 27          | 4,750       |
| Net cash provided by/(used in) investing activities       | _    | (24,676)    | (75,157)    |
| CASH FLOWS FROM FINANCING ACTIVITIES:                     |      |             |             |
| Repayment of lease liabilities                            | _    | (52,124)    | (48,660)    |
| Net cash provided by/(used in) financing activities       | _    | (52,124)    | (48,660)    |
| Net increase/(decrease) in cash and cash equivalents held |      | (56,280)    | (254,748)   |
| Cash and cash equivalents at beginning of year            | _    | 3,440,417   | 3,695,165   |
| Cash and cash equivalents at end of financial year        | 3 =  | 3,384,137   | 3,440,417   |

ABN: 33 113 296 601

#### **Notes to the Financial Statements**

#### For the Year Ended 30 June 2023

#### 1 Summary of Significant Accounting Policies

The Cancer Council ACT (the Company) is a not-for-profit company limited by guarantee, incorporated and domiciled in Australia. The financial statements cover the Company as an individual entity.

#### **Basis of Preparation**

The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards - Simplified Disclosures, Interpretations of the Australian Accounting Standards Board and the Australian Charities and Not-for-profits Commission Act 2012.

The financial statements are presented in Australian dollars which is the Company's functional and presentation currency. The amounts presented in the financial statements have been rounded to the nearest dollar.

The financial statements have been prepared on an accruals basis and are based on historical costs modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

A number of new or revised Australian Accounting Standards are effective for the first time in the current financial year. These standards have had no material impact on the entity.

The following is a summary of the material accounting policies adopted by the Company in the preparation of the financial statements. The accounting policies have been consistently applied, unless otherwise stated.

#### **Accounting Policies**

#### (a) Income tax

The Company is exempt from income tax under the relevant provision of Section 50-40 of the *Income Tax Assessment Act 1997*.

#### (b) Property, plant and equipment

Each class of property, plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation and impairment.

The carrying amount of property, plant and equipment is reviewed at the end of the reporting period to ensure it is not in excess of the recoverable amount from these assets. The recoverable amount is assessed on the basis of expected net cash flows that will be received from the assets' employment and subsequent disposal. The expected net cash flows have been discounted to their present values in determining recoverable amounts.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. All other costs (e.g. repairs and maintenance) are charged to the statement of profit or loss and other comprehensive income during the financial period in which they are incurred.

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains and losses are included in the profit or loss.

ABN: 33 113 296 601

#### **Notes to the Financial Statements**

#### For the Year Ended 30 June 2023

#### **Summary of Significant Accounting Policies (continued)**

#### (b) Property, plant and equipment (continued)

#### **Depreciation Rates**

The depreciable amount of all fixed assets is depreciated on a straight-line basis over the asset's useful life to the Company commencing from the time the asset is held ready for use.

The depreciation rates used for each class of depreciable asset are shown below:

#### **Fixed asset class Depreciation rate** Furniture, plant and equipment 20% straight line

Computer equipment 37.5% straight line

At the end of each annual reporting period, the depreciation method, useful life and residual value of each asset is reviewed. Any revisions are accounted for prospectively as a change in estimate.

#### **Inventories** (c)

Inventories are measured at the lower of cost and net realisable value. Costs are assigned on a first-in first-out basis.

#### Intangible assets (d)

Intangible assets are carried at cost unless otherwise stated and are amortised over their useful life to the Company.

#### Amortisation

Amortisation is calculated on a straight line basis over the useful life of intangible assets, which has been assessed as four years. The amortisation method and useful life of assets is reviewed regularly to ensure they are still appropriate.

#### (e) Leases

At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is considered to contain a lease if it allows the Company the right to control the use of an identified asset over a period of time in return for consideration.

Where a contract or arrangement contains a lease, the Company recognises a right-of-use asset and a lease liability at the commencement date of the lease.

A right-of-use asset is initially measured at cost, which is the present value of future lease payments adjusted for any lease payments made at or before the commencement date, plus any make-good obligations and initial direct costs incurred. Lease assets are depreciated using the straight-line method over the shorter of their useful life and the lease term. Periodic adjustments are made for any re-measurements of the lease liabilities and for impairment losses.

ABN: 33 113 296 601

#### **Notes to the Financial Statements**

#### For the Year Ended 30 June 2023

#### 1 Summary of Significant Accounting Policies (continued)

#### (e) Leases (continued)

Lease liabilities are initially measured at the present value of future minimum lease payments, discounted using the Company's incremental borrowing rate if the rate implicit in the lease cannot be readily determined, and are subsequently measured at amortised cost using the effective interest rate. Minimum lease payments include fixed payments, amounts expected to be paid under a residual value guarantee, the exercise price of purchase options for which the Company is reasonably certain to exercise and incorporate the Company's expectations of lease extension options.

The lease liability is remeasured when there are changes in future lease payments arising from a change in rates, index or lease terms from exercising an extension or termination option. A corresponding adjustment is made to the carrying amount of the lease assets.

Short term leases (lease term of 12 months or less) and leases of low value assets (\$10,000 or less) are recognised as incurred as an expense in the statement of profit or loss and other comprehensive income.

#### (f) Financial instruments

#### Initial recognition and measurement

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions to the instrument. For financial assets, this is the date that the Company commits itself to either the purchase or sale of the asset (i.e. trade date accounting is adopted).

Financial instruments (except for trade receivables) are initially measured at fair value plus transaction costs, except where the instrument is classified 'at fair value through profit or loss', in which case transaction costs are expensed to profit or loss immediately. In most circumstances trade receivables are initially measured at the transaction price.

#### Classification and subsequent measurement

Financial instruments are subsequently measured at either fair value or amortised cost using the effective interest rate method. The subsequent measurement depends on the classification of the financial instrument as described below.

Fair value represents the amount for which an asset could be exchanged or a liability settled, between knowledgeable, willing parties in an arm's length transaction. Where available, quoted prices in an active market are used to determine fair value. In other circumstances, valuation techniques are adopted.

The effective interest method is used to allocate interest income or interest expense over the relevant period.

#### Financial assets

All recognised financial assets are subsequently measured in their entirety at either amortised cost or fair value, depending on the classification of the financial assets.

Financial assets that meet the following conditions are subsequently measured at amortised cost:

 the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and

ABN: 33 113 296 601

#### **Notes to the Financial Statements**

#### For the Year Ended 30 June 2023

#### 1 Summary of Significant Accounting Policies (continued)

#### (f) Financial instruments (continued)

the contractual terms of the financial asset give rise on specified dates to cash flows that are solely
payments of principal and interest on the principal amount outstanding.

Financial assets that meet the following conditions are subsequently measured at fair value through other comprehensive income (FVTOCI):

- the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling the financial assets; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

By default, all other financial assets are subsequently measured at fair value through profit or loss (FVTPL).

Despite the above, the Company may make the following irrevocable election/designation at initial recognition of a financial asset:

- the Company may irrevocably elect to present subsequent changes in fair value of an equity instrument in other comprehensive income if certain criteria are met: and
- the Company may irrevocably designate a financial asset that meets the amortised cost or FVTOCI criteria as measured at FVTPL if doing so eliminates or significantly reduces an accounting mismatch.

#### Financial liabilities

All financial liabilities are subsequently measured at amortised cost using the effective interest method or at FVTPL.

#### Impairment of financial assets

The Company recognises a loss allowance for expected credit losses on financial assets that are measured at amortised cost or at FVTOCI. No impairment loss is recognised for investments in equity instruments. The amount of expected credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the respective financial asset.

The Company recognises lifetime expected credit losses for trade receivables. The expected credit losses on these financial assets are estimated based on the Company's historical credit loss experience adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current as well as the future direction of conditions at the reporting date, including time value of money where appropriate.

#### (g) Impairment of non-financial assets

At the end of each reporting period, the Company reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, is compared to the asset's carrying value. Any excess of the asset's carrying value over its recoverable amount is expensed to the profit or loss.

Where it is not possible to estimate the recoverable amount of an individual asset, the recoverable amount of the cash generating unit to which the asset belongs is estimated.

ABN: 33 113 296 601

#### **Notes to the Financial Statements**

#### For the Year Ended 30 June 2023

#### 1 Summary of Significant Accounting Policies (continued)

#### (h) Employee benefits

Provision is made for the Company's liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits that are expected to be settled within one year have been measured at the amounts expected to be paid when the liability is settled plus related on-costs. Employee benefits expected to be settled more than twelve months after the end of the reporting period have been measured at the present value of the estimated future cash outflows to be made for those benefits. Long service leave entitlements of staff are funded through contributions to the ACT Community Sector Portable Long Service Leave Scheme.

Contributions are made by the Company to employee superannuation funds and are charged as expenses when incurred.

#### (i) Provisions

Provisions are recognised when the Company has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.

#### (j) Cash and cash equivalents

Cash and cash equivalents comprises cash on hand, demand deposits and short-term investments which are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

#### (k) Revenue and other income

Revenue is measured at the amount which the Company expects to receive in consideration for satisfying performance obligations to a customer. A performance obligation is the distinct good or service defined within the contract with a customer. The transaction price is allocated to one or more performance obligations contained within the contract, with revenue being recognised as or when the performance obligation is satisfied.

#### Timing of Revenue Recognition

Revenue is recognised either at a point in time or over time, when (or as) the Company satisfies performance obligations by transferring the promised goods or services to its customers.

If the Company satisfies a performance obligation before it receives the consideration, the Company recognises either a contract asset or a receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due.

#### Goods and services

Revenue from the sale of merchandise is recognised upon delivery of the goods to customers (point in time). Revenue from the rendering of a service is recognised upon the delivery of the service to the customers (point in time).

Special events, donations, bequests and membership fees

Donations, bequests and membership fees are recognised as income when received except for amounts receivable from other State Cancer Council's where an existing arrangement is in place that establishes an entitlement to the monies receivable which are recognised when the right to receive the contributions is confirmed.

ABN: 33 113 296 601

#### **Notes to the Financial Statements**

#### For the Year Ended 30 June 2023

#### 1 Summary of Significant Accounting Policies (continued)

#### (k) Revenue and other income (continued)

#### Grants

Where performance obligations for the grants are not sufficiently specific, the Company recognises revenue when it gains control of (or has the right to receive) the asset (cash), within the scope of AASB 1058 Income for Not-for-Profit Entities.

Where a grant is subject to specific performance obligations and conditions that must be satisfied by the Company, revenue is recognised in the period in which contract costs are incurred for which the government funding is intended to compensate provided all attaching conditions have been complied with and the performance obligations under the contract have been met (within the scope of AASB 15 Revenue from Contracts with Customers). Revenue received where the cost to which it relates has not yet been incurred is deferred by recognition of a contract liability in the Statement of Financial Position.

#### Fundraising events

Revenue and costs from fundraising events that have a specific performance obligation are recognised as revenue and expense on completion of the event (point in time). Income received and expenses incurred prior to event are recognised as income in advance (contract liabilities, unexpended funds) and prepayments (other assets) respectively.

#### Interest income

Interest income is recognised on an accruals basis using the effective interest method.

#### Dividend and royalty income

Dividend and royalty income is recognised when received.

All revenue is stated net of the amount of goods and services tax (GST).

#### (I) Goods and services tax (GST)

Revenue, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are stated inclusive GST.

Cash flows in the statement of cash flows are included on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

#### (m) Comparative amounts

Comparative figures have been adjusted, where necessary to conform to changes in presentation for the current financial year.

ABN: 33 113 296 601

## **Notes to the Financial Statements**

#### For the Year Ended 30 June 2023

#### **Critical Accounting Estimates and Judgments**

The Directors evaluate estimates and judgments incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Company.

The Directors do not believe that there were any key estimates or key judgments used in the development of the financial statements that give rise to a significant risk of material adjustment in the future.

#### 2 Revenue and Other Income

|                                       | 2023      | 2022      |
|---------------------------------------|-----------|-----------|
|                                       | \$        | \$        |
| Revenue from contracts with customers |           |           |
| Revenue recognised over time          |           |           |
| Grants                                | 547,844   | 379,933   |
| Revenue recognised at a point in time |           |           |
| Wig service                           | 20,113    | 656       |
| Online retail sales                   | 11,899    | 12,245    |
| Other products and services           | 660       | 10,196    |
|                                       | 580,516   | 403,030   |
| Other income                          |           |           |
| Membership fees                       | 241       | 382       |
| Donations                             | 620,806   | 678,170   |
| Special events                        | 811,144   | 574,236   |
| Bequests                              | 295,889   | 187,388   |
| Interest received                     | 86,056    | 6,627     |
| Royalties                             | 68,522    | 47,475    |
| Gain on sale of assets                | 27        | 2,217     |
| Sundry income                         | 25,998    | -         |
|                                       | 1,908,683 | 1,496,495 |
|                                       | 2,489,199 | 1,899,525 |
| Cash and Cash Equivalents             |           |           |
| ·                                     | 2023      | 2022      |
|                                       | \$        | \$        |
| Cash at bank                          | 3,362,866 | 3,419,146 |
| Deposits at call                      | 21,271    | 21,271    |
|                                       | 3,384,137 | 3,440,417 |

ABN: 33 113 296 601

## **Notes to the Financial Statements**

## For the Year Ended 30 June 2023

#### 4 Trade and Other Receivables

| 4 | Trade and Other Receivables  |           |           |
|---|--|-----------|-----------|
|   |  | 2023      | 2022      |
|   |  | \$        | \$        |
|   | CURRENT  |           |           |
|   | Other receivables  | 70,725    | 5,498     |
|   | GST receivables  | 9,589     | 34,767    |
|   | Amounts receivable from related party - Cancer Council Australia       | 200,817   | 130,079   |
|   | Amounts receivable from related party - Cancer Council New South Wales | 24,860    | 59,209    |
|   | Amounts receivable from related party - Cancer Council Victoria        | 1,434     | 1,533     |
|   |  | 307,425   | 231,086   |
| 5 | Other Assets   |           |           |
|   |  | 2023      | 2022      |
|   |  | \$        | \$        |
|   | Prepayments  | 25,729    | 38,817    |
| 6 | Property, Plant and Equipment  |           |           |
|   |  | 2023      | 2022      |
|   |  | \$        | \$        |
|   | Furniture, plant and equipment   |           |           |
|   | At cost  | 90,962    | 90,922    |
|   | Accumulated depreciation   | (87,339)  | (68,842)  |
|   |  | 3,623     | 22,080    |
|   | Computer equipment   |           |           |
|   | At cost  | 176,594   | 170,120   |
|   | Accumulated depreciation   | (168,388) | (146,465) |
|   |  | 8,206     | 23,655    |
|   |  | 11,829    | 45,735    |
|   |  |           |           |

## Movements in carrying amounts

Movement in the carrying amounts for each class of property, plant and equipment between the beginning and the end of the current financial year:

|                                  | Furniture,<br>plant and<br>equipment | Computer equipment | Total    |
|----------------------------------|--------------------------------------|--------------------|----------|
|                                  | \$                                   | \$                 | \$       |
| Year ended 30 June 2023          |                                      |                    |          |
| Balance at the beginning of year | 22,080                               | 23,655             | 45,735   |
| Additions                        | 40                                   | 6,474              | 6,514    |
| Depreciation expense             | (18,497)                             | (21,923)           | (40,420) |
| Balance at the end of the year   | 3,623                                | 8,206              | 11,829   |

ABN: 33 113 296 601

7

8

# **Notes to the Financial Statements**

# For the Year Ended 30 June 2023

| Intangible Assets  |                      |          |
|--|----------------------|----------|
|  | 2023                 | 2022     |
|  | \$                   | \$       |
| Computer software  |                      |          |
| At cost  | 74,519               | 56,330   |
| Accumulated amortisation                                     | (10,466)             | <u>-</u> |
| Total Intangible assets                                      | 64,053               | 56,330   |
| Movements in carrying amounts of intangible assets           |                      |          |
|  | Computer<br>software | Total    |
|  | \$                   | \$       |
|  | •                    | Ψ        |
| Year ended 30 June 2023 Balance at the beginning of the year | 56,330               | 56,330   |
| Additions  | 18,189               | 18,189   |
| Accumulated amortisation                                     | (10,466)             | (10,466) |
| Balance at the end of the year                               | 64,053               | 64,053   |
| Trade and Other Payables                                     |                      |          |
|  | 2023                 | 2022     |
|  | \$                   | \$       |
| CURRENT  |                      |          |
| Trade payables   | 122,393              | 114,707  |
| Accrued expenses   | 78,732               | 85,932   |
| PAYG payable   | 18,062               | 16,930   |
| Employee benefits payable                                    | (388)                | 25,348   |
| Other payables   | 6,146                | 753      |

243,670

224,945

# **Notes to the Financial Statements**

# For the Year Ended 30 June 2023

| 9  | Leases  |                    |                    |
|----|---|--------------------|--------------------|
|    |   | 2023               | 2022               |
|    |   | \$                 | \$                 |
|    | Right-of-use assets At cost                                       |                    |                    |
|    | Balance at 1 July   | 934,762            | 934,762            |
|    | Additions in the year   | -                  | -                  |
|    | Expired during the year   |                    |                    |
|    | Balance at the end of the year                                    | 934,762            | 934,762            |
|    | Accumulated amortisation  |                    |                    |
|    | Balance at 1 July   | (187,010)          | (123,297)          |
|    | Amortisation for the year   | (63,713)           | (63,713)           |
|    | Balance at the end of the year                                    | (250,723)          | (187,010)          |
|    | Net book value  | 684,039            | 747,752            |
|    |   |                    |                    |
|    | Lease liabilities   |                    |                    |
|    | Current   | 55,766             | 52,125             |
|    | Non-current   | 687,592            | 743,357            |
|    |   | 743,358            | 795,482            |
|    | Total future lease payments at the end of the reporting period:   |                    |                    |
|    | Not later than one year   | 85,501             | 84,271             |
|    | Between one year and five years  Later than five years            | 349,830<br>469,878 | 346,999<br>558,210 |
|    | Later than live years   | 905,209            | 989,480            |
|    | The Company's leases relate to office premises and a photocopier. |                    |                    |
|    | The Company's leases relate to office premises and a photocopier. |                    |                    |
| 10 | Contract Liabilities  |                    |                    |
|    |   | 2023               | 2022               |
|    |   | \$                 | \$                 |
|    | Unexpended funds  | 96,725             | 136,341            |
| 11 | Employee Benefits   |                    |                    |
| -  |   | 2023               | 2022               |
|    |   | \$                 | \$                 |
|    | Provision for annual leave  | 41,658             | 48,739             |

ABN: 33 113 296 601

#### **Notes to the Financial Statements**

#### For the Year Ended 30 June 2023

#### 12 Financial Risk Management

The Company's financial instruments consist mainly of deposits with banks, accounts receivable and payable.

The carrying amount for each category of financial instruments, measured in accordance with AASB 9: Financial Instruments as detailed in the accounting policies to these financial statements are as follows:

|  |      | 2023      | 2022      |
|--|------|-----------|-----------|
|  | Note | \$        | \$        |
| Financial assets                         |      |           |           |
| Financial assets at amortised cost:      |      |           |           |
| Cash and cash equivalents                | 3    | 3,384,137 | 3,440,417 |
| Trade and other receivables              | 4    | 307,425   | 231,086   |
| Total financial assets                   | =    | 3,691,562 | 3,671,503 |
| Financial liabilities                    |      |           |           |
| Financial liabilities at amortised cost: |      |           |           |
| Trade and other payables                 | 8 _  | 224,945   | 243,670   |
| Total financial liabilities              | _    | 224,945   | 243,670   |

#### 13 Members' Guarantee

The Company is limited by guarantee. If the Company is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the Company. At 30 June 2023 the number of members was 15 (2022: 17).

#### 14 Key Management Personnel Remuneration

Key management personnel is defined by AASB 124 "Related Party Disclosures" as those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director of the Company.

The total of remuneration paid to the key management personnel of the Company during the year is:

|    |   | 2023    | 2022    |
|----|---|---------|---------|
|    |   | \$      | \$      |
|    | Total key management personnel compensation | 231,693 | 206,176 |
|    |   |         |         |
| 15 | Auditors' Remuneration                      |         |         |
|    |   | 2023    | 2022    |
|    |   | \$      | \$      |
|    | Audit of the financial statements           | 14,000  | 14,120  |

ABN: 33 113 296 601

#### **Notes to the Financial Statements**

#### For the Year Ended 30 June 2023

#### 16 Contingencies

The Company has no contingent liabilities or contingent assets at the end of the financial year (30 June 2022: None)

#### 17 Related Parties

All transactions during the year were on normal commercial terms and conditions unless otherwise stated.

The Company is a member of and has a common director with Cancer Council Australia. The Company and other membership organisations in each state and territory contribute annual membership fees, purchase fundraising merchandise and received net fundraising income from Cancer Council Australia.

#### 18 Events After the Reporting Date

These financial statements were authorised for issue by the directors on the date of signing the attached Directors' Declaration. The directors have the right to amend and re-issue the financial statements after they are issued.

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Company, the results of those operations or the state of affairs of the Company in future financial years.

#### 19 Company Details

The registered office and principal place of business of the Company is:

The Cancer Council ACT Unit 1, 173 Strickland Crescent Deakin ACT 2600

ABN: 33 113 296 601

## **Directors' Declaration**

The directors of The Cancer Council ACT (the Company) declare that:

- 1. The financial statements and notes, as set out on pages 7 to 22, are in accordance with the Australian Charities and Not-for-profits Commission Act 2012 and:
  - a. comply with Australian Accounting Standards Simplified Disclosures; and
  - b. give a true and fair view of the company's financial position as at 30 June 2023 and of its performance for the year ended on that date.
- 2. In the directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

Director

Dated:

25 October 2023



Nexia Canberra
Level 5, 17 Moore Street
Canberra ACT 2601
GPO Box 500
Canberra ACT 2601

P: +61 2 6279 5400

# **Independent Auditor's Report To the Members of The Cancer Council ACT**

#### **Report on the Audit of the Financial Statements**

#### **Qualified Opinion**

We have audited the financial statements of The Cancer Council ACT (the Company) which comprise the statement of financial position as at 30 June 2023, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration.

In our opinion except for the effects on the financial statements of the matter referred to in the Basis for qualified opinion paragraph below, the accompanying financial statements of the Company, are in accordance with Divison 60 of the Australian Charities and Not-for-profits Commission Act 2012, including:

- (i) giving a true and fair view of the Company's financial position as at 30 June 2023 and of its financial performance for the year then ended; and
- (ii) complying with Australian Accounting Standards Simplified Disclosures and Division 60 of the Australian Charities and Not-for-profits Commission Regulation 2022.

#### **Basis for qualified opinion**

As is common for organisations of this type, it was not practical to maintain an effective system of internal control over the completeness of revenue from certain donations and fundraising activities. Accordingly, our audit in relation to revenue from certain donations and fundraising activities for the financial year was limited to the amounts recorded as banked by the Company.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Association in accordance with the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to our audit of the financial statements in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Other information**

The directors are responsible for the other information. The other information comprises the information in the Company's directors' report for the year ended 30 June 2023, but does not include the financial statements and the auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

## Audit. Tax. Advisory.



In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of the other information we are required to report that fact. We have nothing to report in this regard.

#### **Directors' responsibility for the financial statements**

The directors of the Company are responsible for the preparation of the financial statements that give a true and fair view in accordance with Australian Accounting Standards – Simplified Disclosures and the Australian Charities and Not-for-profits Commission Act 2012 and for such internal control as the directors determine is necessary to enable the preparation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the entity or to cease operations, or have no realistic alternative but to do so.

The directors are responsible for overseeing the entity's financial reporting process.

#### Auditor's responsibility for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

A further description of our responsibilities for the audit of the financial statements is located at The Australian Auditing and Assurance Standards Board website at:

http://www.auasb.gov.au/auditors\_responsibilities/ar4.pdf. This description forms part of our auditor's report.

**Nexia Duesburys (Audit)** 

min Muller

Canberra, 25 October 2023

G J Murphy Partner

Juny Muly

# How you can help



**DONATE** 



OO CO.

VOLUNTEER









Unit 1/173 Strickland Crescent
Deakin ACT 2600
02 6257 9999
reception@actcancer.org

